By Honorary Professor Mark Thomas Sullivan

Journal articles

Rayner CR; Martin NE; Smith D; Kruger E; Kirkpatrick CMJ; Pillai G; Moore K; Nix D; Donini C; Cramer JP; Muniz E; Muniz N; Bos E; McNair D; Bhaskaran S; Sullivan M; Hartman D, 2026, 'The Governance Gap: Democratizing Drug Development Through Decision Architecture', Clinical Pharmacology and Therapeutics, http://dx.doi.org/10.1002/cpt.70476

Sullivan M, 2025, 'Rethinking pharmaceutical development: A not-for-profit model to address global health inequities', Future Healthcare Journal, 12, pp. 100255, http://dx.doi.org/10.1016/j.fhj.2025.100255

Wood ND; Smith D; Kinrade SA; Sullivan MT; Rayner CR; Wesche D; Patel K; Rowland-Yeo K, 2024, 'The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation', Plos Neglected Tropical Diseases, 18, http://dx.doi.org/10.1371/journal.pntd.0012351

Tan B; Opoku N; Attah SK; Awadzi K; Kuesel AC; Lazdins-Helds J; Rayner C; Ryg-Cornejo V; Sullivan M; Fleckenstein L, 2022, 'Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection', Plos Neglected Tropical Diseases, 16, http://dx.doi.org/10.1371/journal.pntd.0010005

Begley CG; Ashton M; Baell J; Bettess M; Brown MP; Carter B; Charman WN; Davis C; Fisher S; Frazer I; Gautam A; Jennings MP; Kearney P; Keeffe E; Kelly D; Lopez AF; McGuckin M; Parker MW; Rayner C; Roberts B; Rush JS; Sullivan M, 2021, 'Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers', Science Translational Medicine, 13, http://dx.doi.org/10.1126/scitranslmed.abd5524

Anderson RL; Balasas T; Callaghan J; Coombes RC; Evans J; Hall JA; Kinrade S; Jones D; Jones PS; Jones R; Marshall JF; Panico MB; Shaw JA; Steeg PS; Sullivan M; Tong W; Westwell AD; Ritchie JWA, 2019, 'A framework for the development of effective anti-metastatic agents', Nature Reviews Clinical Oncology, 16, pp. 185 - 204, http://dx.doi.org/10.1038/s41571-018-0134-8

Olliaro PL; Kuesel AC; Halleux CM; Sullivan M; Reeder JC, 2018, 'Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years', Plos Neglected Tropical Diseases, 12, http://dx.doi.org/10.1371/journal.pntd.0006837

Kinrade SA; Mason JW; Sanabria CR; Rayner CR; Bullock JM; Stanworth SH; Sullivan MT, 2018, 'Evaluation of the Cardiac Safety of Long-Acting Endectocide Moxidectin in a Randomized Concentration-QT Study', Clinical and Translational Science, 11, pp. 582 - 589, http://dx.doi.org/10.1111/cts.12583

Wyber R; Boyd BJ; Colquhoun S; Currie BJ; Engel M; Kado J; Karthikeyan G; Sullivan M; Saxena A; Sheel M; Steer A; Mucumbitsi J; Zühlke L; Carapetis J, 2016, 'Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever', Drug Delivery and Translational Research, 6, pp. 572 - 578, http://dx.doi.org/10.1007/s13346-016-0313-z

Kløverpris HN; Jackson A; Handley A; Hayes P; Gilmour J; Riddell L; Chen F; Atkins M; Boffito M; Walker BD; Ackland J; Sullivan M; Goulder P, 2013, 'Non-Immunogenicity of Overlapping Gag Peptides Pulsed on Autologous Cells after Vaccination of HIV Infected Individuals', Plos One, 8, http://dx.doi.org/10.1371/journal.pone.0074389

Jackson A; Kløverpris HN; Boffito M; Handley A; Atkins M; Hayes P; Gilmour J; Riddel L; Chen F; Bailey-Tippets M; Walker B; Ackland J; Sullivan M; Goulder P, 2013, 'A Randomised, Placebo-Controlled, First-In-Human Study of a Novel Clade C Therapeutic Peptide Vaccine Administered Ex Vivo to Autologous White Blood Cells in HIV Infected Individuals', Plos One, 8, http://dx.doi.org/10.1371/journal.pone.0073765

Jackson A; Kløverpris H; Handley A; Hayes P; Gilmour J; Atkins M; Walker B; Ackland J; Sullivan M; Goulder P, 2012, 'A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART', Retrovirology, 9, pp. o54, http://dx.doi.org/10.1186/1742-4690-9-s2-o54

Kløverpris H; Jackson A; Handley A; Hayes P; Gilmour J; Atkins M; Walker B; Ackland J; Sullivan M; Goulder P, 2012, 'Immune response after vaccination of HIV infected individuals receiving HAART with overlapping gag peptides pulsed on autologous cells', Retrovirology, 9, pp. p115, http://dx.doi.org/10.1186/1742-4690-9-s2-p115

Brown GJ; Daveson J; Marjason JK; Ffrench RA; Smith D; Sullivan M; Tye-Din JA; Anderson RP, 2011, 'A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2® in HLA DQ2+ Volunteers With Celiac Disease Following a Long-Term, Strict Gluten-Free Diet', Gastroenterology, 140, pp. s-437-s-438, http://dx.doi.org/10.1016/s0016-5085(11)61794-0

Kloverpris Henrik H; Fomsgaard A; Handley A; Ackland J; Sullivan M; Goulder P, 2010, 'Dimethyl sulfoxide (DMSO) exposure to human peripheral blood mononuclear cells (PBMCs) abolish T cell responses only in high concentrations and following coincubation for more than two hours', Journal of Immunological Methods, 356, pp. 70 - 78, http://dx.doi.org/10.1016/j.jim.2010.01.014

Sullivan M, 2009, 'Moving candidate vaccines into development from research: Lessons from HIV', Immunology and Cell Biology, 87, pp. 366 - 370, http://dx.doi.org/10.1038/icb.2009.30

De Rose R; Sullivan MT; Dale CJ; Kelleher AD; Emery S; Cooper DA; Ramshaw I; Boyle D; Kent SJ, 2006, 'Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines.', Human Vaccines, 2, pp. 134 - 136

De Rose R; Chea S; Dale C; Reece J; Fernandez C; Wilson K; Thomson S; Ramshaw I; Coupar B; Boyle D; Sullivan MT; Kent S, 2005, 'Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques', Vaccine, 23, pp. 1949 - 1956, http://www.sciencedirect.com/science/article/B6TD4-4DS4075-2/2/4ac957fc8ef72984bea88998a0965b95

Hannon H; Bagnis CI; Benhamou Y; Beaufils H; Sullivan M; Brosgart C; Izzedine H; Poynard T; Deray G, 2004, 'The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV', Nephrology Dialysis Transplantation, 19, pp. 386 - 390, http://dx.doi.org/10.1093/ndt/gfg505

Peters MG; Hann HW; Martin P; Heathcote EJ; Buggisch P; Rubin R; Bourliere M; Kowdley K; Trepo C; Gray DF; Sullivan M; Kleber K; Ebrahimi R; Xiong S; Brosgart CL, 2004, 'Adefovir Dipivoxil Alone or in Combination with Lamivudine in Patients with Lamivudine-Resistant Chronic Hepatitis B', Gastroenterology, 126, pp. 91 - 101, http://dx.doi.org/10.1053/j.gastro.2003.10.051

Marcellin P; Hadzyannis S; Schiff E; Peters M; Benhamou Y; Brosgart C; Fry J; Wulfsohn M; Sullivan M; Currie GM, 2003, 'Adefovir dipivoxil 10 mg (ADV) results in consistent efficacy in chronic hepatitis B (CHB) patients with diverse baseline characteristics', Journal of Hepatology, 38, pp. 153 - 154, http://dx.doi.org/10.1016/s0168-8278(03)80795-x

Peters M; Martin P; Sullivan M; Kleber K; Ebrahimi R; Westland C; Delaney WE; Xiong S; Brosgart C, 2003, 'Changes in alanine aminotransferase (ALT) and YMDD mutation profile associated with switching from lamivudine (LAM) to either adefovir dipivoxil (ADV) or combination LAM plus ADV in chronic hepatitis B (CHB) patients with LAM resistance', Gastroenterology, 124, pp. A715 - A715, http://dx.doi.org/10.1016/s0016-5085(03)83608-9

Westland CE; Yang H; Delaney WE; Thibault V; Benhamou Y; Gibbs CS; Miller MD; Wulfsohn M; Sullivan M; Fry J; Brosgart CL; Xiong S, 2003, 'Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy', Journal of Hepatology, 38, pp. 182 - 182, http://dx.doi.org/10.1016/s0168-8278(03)80004-1

Peters M; Hann HW; Martin P; Heathcote E; Buggisch P; Moorat AE; Sullivan M; Kleber K; Ebrahimi R; Xiong S; Brosgart C, 2002, 'Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis', Journal of Hepatology, 36, pp. 6 - 7, http://dx.doi.org/10.1016/s0168-8278(02)80013-7

Westland C; Gibbs C; Miller M; Sullivan M; Fry J; Brosgart C; Wulfsohn M; Xiong S, 2002, 'Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy', Journal of Hepatology, 36, pp. 7 - 7, http://dx.doi.org/10.1016/s0168-8278(02)80015-0

Benhamou Y; Bochet M; Thibault V; Calvez V; Fievet MH; Sullivan M; Brosgart C; Namini H; Poynard T; Katlama C, 2002, 'Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients', Journal of Hepatology, 36, pp. 138 - 138, http://dx.doi.org/10.1016/s0168-8278(02)80496-2

Benhamou Y; Bochet M; Tubiana R; Thibault V; Suflisseau L; Sullivan M; Rooney J; Brosgart C; Bricaire F; Katlama C; Poynard T, 2002, 'Tenofovir disoproxil fumarate (TDF) suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV', Journal of Hepatology, 36, pp. 138 - 138, http://dx.doi.org/10.1016/s0168-8278(02)80495-0

Back to profile page